Pediatric vaccine propels sharp drop in meningitis cases
Allergic rhinitis does not appear to be associated with snoring or daytime sleepiness, but individuals with obstructed nasal passages are likely to experience both regardless of whether they have allergies, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery. Nasal obstruction is one of the most troublesome symptoms of
Full Post: Allergic rhinitis not associated with snoring or daytime sleepiness
A pediatric vaccine with University of Rochester roots has proven to be highly successful at reducing cases of bacterial meningitis across all age groups.That is the conclusion of a seven-year study, the results of which appeared today in the New England Journal of Medicine.
“This is a very effective vaccine and a textbook example of herd immunity,” said Nancy M. Bennett, M.D., M.S., professor of Medicine, director of the Center for Community Health at the University of Rochester Medical Center, and deputy director of the Monroe County Department of Public Health.”Even though the vaccine is only given to infants, it has proven highly effective in reducing infections among people who don’t get vaccine, as well as among those who do.”
The pediatric pneumococcal conjugate vaccine, which is marketed under the brand name Prevnar by Wyeth, was introduced in 2000, and a year later the CDC recommended that it be given to all children younger than 2 years. The vaccine was created using a “conjugate” vaccine platform that was developed by URMC pediatric researchers in the 1980s.The process makes a vaccine more effective by linking it to a protein that spurs an infant’s immune system to fight an infection especially vigorously.
Prevnar is designed to provide immunity to 7 serotypes - or strains - of the bacteria streptococcus pneumoniae.While commonly associated with pneumonia and blood infections, pneumococcus is also the most common cause of bacterial meningitis - a potentially life threatening inflammation in the central nervous system.
Bennett - a co-author of the study - oversees the Rochester Emerging Infections Program, one of several sites in a national surveillance and research network funded by the Centers for Disease Control and Prevention (CDC).The network tracks the epidemiology of several bacterial and viral diseases that are preventable by vaccines and evaluates the effectiveness of new vaccines after they have been introduced.The other sites included in the study are Baltimore, Connecticut, Minnesota, Tennessee, San Francisco, Atlanta, and Oregon.
The study included data on 1379 cases of pneumococcal meningitis between 1998 and 2006; 71 of the cases were from the 7-county Rochester region. By the end of the seven-year period, researchers found that incidence of meningitis caused by all serotypes had declined by more than 30% across all age groups.Meningitis caused by the 7 strains in the vaccine declined 73%. The vaccine even reduced infection rates in serotypes of the disease that were related to, but genetically different from the ones targeted by the vaccine.
In a finding that was a cause for concern, the researchers also saw a small increase in disease caused by serotypes that are not included in Prevnar.However, the overall decline in disease far outweighed the small increase in the disease caused by the serotypes not included in the vaccine.Researchers also point out that there are new vaccines under development that may provide protection from these strains.
One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm
Full Post: Fractional dose of scarce meningitis vaccine may be effective in outbreak control
Australian scientists have discovered a bacteria which could stop meningitis - the scientists at the University of Western Australia believe their discovery will help researchers understand how the meningitis bacteria infects cells and could lead to the prevention of infections such as meningitis. The bacteria Neisseria meningitidis which causes the disease in humans is
Full Post: Australian scientists discover a way to stop meningitis
Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome. Malaria is caused by Plasmodium falciparum, the most deadly malaria parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five
Full Post: Vaccine against malaria could be ready in 5 years
The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries. Each year, an estimated 1.1 million people die from Shigella infections, a major cause of diarrhea and dysentery,
Full Post: Live oral Shigella vaccine licensed to PATH
Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia. It also causes blood stream infections and brain infections. According to the Centers for Disease Control, pneumococcal infection is one of the leading causes
Full Post: Adults with asthma at increased risk of serious pneumococcal disease